 |
|
COMMENTS AND OPINIONS
Risks of Combining Immunosuppressive and Biological Treatments in Inflammatory Bowel Disease
Xavier Roblin, MD;
Jean Marc Phelip, MD, PhD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Sorrentino et al1 report the results of infliximab with low-dose methotrexate for the prevention of postsurgical recurrence of ileocolonic Crohn disease (CD). The authors elected to coadminister methotrexate because it is known to reduce the long-term immunogenicity of infliximab.2 This is true only with episodic treatment with infliximab. Despite the observation that therapy with concomitant immunosuppressive agents reduces the development of antibodies against biological treatments, the authors have not significantly altered the response to infliximab3 in the treatment of CD when the agents are administered as an induction course followed by scheduled maintenance treatment. Recently, Maser et al4 demonstrated that the rate of clinical remission was higher for patients with a detectable trough serum concentration of infliximab compared with patients in whom serum infliximab was undetectable, including those without antibodies (82% vs 6%; P < .001). In this study, concurrent immunomodulators did not . . . [Full Text of this Article]
AUTHOR INFORMATION
RELATED LETTERS
Infliximab With Low-Dose Methotrexate for Prevention of Postsurgical Recurrence of Ileocolonic Crohn Disease
Dario Sorrentino, Giovanni Terrosu, Claudio Avellini, and Stefania Maiero
Arch Intern Med. 2007;167(16):1804-1807.
EXTRACT
| FULL TEXT
Risks of Combining Immunosuppressive and Biological Treatments in Inflammatory Bowel Disease—Reply
Dario Sorrentino, Giovanni Terrosu, and Claudio Avellini
Arch Intern Med. 2008;168(6):667-668.
EXTRACT
| FULL TEXT
|
